{"name": "ThromboGenics",
 "permalink": "thrombogenics",
 "crunchbase_url": "http://www.crunchbase.com/company/thrombogenics",
 "homepage_url": "http://thrombogenics.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@thrombogenics.com",
 "phone_number": "+32 (0) 16 75 13 10",
 "description": "",
 "created_at": "Sat Mar 17 03:33:49 UTC 2012",
 "updated_at": "Sat Mar 17 03:36:47 UTC 2012",
 "overview": "\u003Cp\u003EThromboGenics is a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines. The Company\u2019s lead product, ocriplasmin, has successfully completed two Phase III clinical trials for the pharmacological treatment of symptomatic vitreomacular adhesion (VMA). The MAA for ocriplasmin has been accepted for review in Europe and the BLA will be re-submitted in the U.S. by April 2012. Ocriplasmin is in Phase II clinical development for additional vitreoretinal conditions.\nThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International. These include TB-402 (anti-Factor VIII), a long-acting anticoagulant in Phase II, and TB-403 (anti-PlGF), in Phase Ib/II for cancer in partnership with Roche.\nThromboGenics is headquartered in Leuven, Belgium. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       24],
      "assets/images/resized/0017/9258/179258v1-max-150x150.png"],
     [[250,
       40],
      "assets/images/resized/0017/9258/179258v1-max-250x250.png"],
     [[324,
       53],
      "assets/images/resized/0017/9258/179258v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "CEO",
    "person":
     {"first_name": "Patrik",
      "last_name": "De Haes",
      "permalink": "patrik-de-haes",
      "image": null}},
   {"is_past": false,
    "title": "CFO",
    "person":
     {"first_name": "Chris",
      "last_name": "Buyse",
      "permalink": "chris-buyse",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "Gaston Geenslaan 1",
    "address2": "",
    "zip_code": "B-3001",
    "city": "Heverlee",
    "state_code": null,
    "country_code": "BEL",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "Novartis grabs rights to eye drug in $494M deal",
    "stoned_year": 2012,
    "stoned_month": 3,
    "stoned_day": 16,
    "source_url": "http://www.fiercebiotech.com/story/novartis-grabs-rights-eye-drug-494m-deal/2012-03-16?utm_medium=rss\u0026utm_source=rss",
    "source_text": "",
    "source_description": "Novartis grabs rights to eye drug in $494M deal",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "ThromboGenics",
      "permalink": "thrombogenics"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}